Roche discontinues dosing for Huntington's disease treatment

FILE PHOTO: A sign at a diagnostics site for Swiss pharmaceutical giant Roche is seen, in Burgess Hill, Britain, October 7, 2020. REUTERS/Peter Nicholls/File Photo

ZURICH (Reuters) – Roche said on Monday it decided to discontinue dosing in a phase III study of tominersen in manifest Huntington’s disease, a rare genetic disease with no approved therapies.

The decision was based on the results of a pre-planned review of the data from the GENERATION HD1 Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC) that made its recommendation based on the investigational therapy’s potential benefit/risk profile for study participants, Roche said in a statement.

Source: Read Full Article